(Q37397924)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

review article

1 reference

title

Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Peter J Frederick

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

J Michael Straughn

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Ronald D Alvarez

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

20 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

384-390

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

New, expanded, and modified use of approved antineoplastic agents in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Monoclonal antibodies in cancer therapy: 25 years of progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Biologic and therapeutic role of HER2 in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Humanization of an anti-p185HER2 antibody for human cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Kinase inhibitors in cancer therapy: a look ahead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

The epidermal growth factor receptor and its inhibition in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Epidermal growth factor-related peptides and their receptors in human malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Mechanisms for oncogenic activation of the epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Role of an anti-epidermal growth factor receptor in treating cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Reactivity of a monoclonal antibody with human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Biologic and Immunologic Therapies for Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA 125 Murine Monoclonal Antibody B43.13

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

Immunotherapy for gynaecological malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.008

10.1016/J.YGYNO.2009.01.008

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232697%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference